A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Glaucoma
Interventions
DRUG

bimatoprost ophthalmic solution formulation A

1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.

DRUG

timolol ophthalmic solution

1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.

DRUG

bimatoprost vehicle

1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.

Trial Locations (9)

Unknown

Louisville

Amiens

Milan

Parma

City of Taguig

Makati

Seoul

Taipei

London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY